EMERGING ROLE OF MAVACAMTEN IN PRECISION MEDICINE FOR HYPERTROPHIC CARDIOMYOPATHY

Mavacamten is a first-in-class, orally administered, selective allosteric inhibitor of beta-cardiac myosin ATPase. Its novel mechanism directly targets the core pathophysiology by reducing the formation of actin-myosin cross-bridges, shifting myosin heads towards a relaxed, energy-sparing state. This action decreases myocardial contractility and alleviates LVOT obstruction in an exposure-dependent manner. Hypertrophic cardiomyopathy (HCM), a prevalent genetic myocardial disorder, is characterized by hypercontractility which often leads to dynamic left ventricular outflow tract (LVOT) obstruction in the obstructive phenotype (oHCM). Traditional pharmacotherapies, such as beta-blockers and calcium channel blockers, offer symptomatic relief but are non-specific and often inadequate. Critically, the VALOR-HCM trial demonstrated that mavacamten substantially reduced the proportion of patients eligible for septal reduction therapy (SRT), positioning it as a potent non-invasive alternative. Mavacamten is extensively metabolized primarily by the polymorphic CYP2C19 enzyme, resulting in a highly variable half-life (6–9 days in normal metabolizers, approximately 23 days in poor metabolizers). Mavacamten represents a paradigm shift from symptomatic management to a disease-specific approach for oHCM. While long-term data and strategies for managing its complex pharmacogenetics continue to evolve, it establishes a foundational advance in the medical management of this condition.

• Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hyper-trophic ardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J., 2014; 35: 2733---79.
• Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardi-ology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2020; 142: e558---631.
• Elliott P, Andersson B, Arbustini E, et al. Classification of the car-diomyopathies: a position statement from the European Society of Cardiology working group on myocardial and pericardial dis-eases. Eur Heart J., 2008; 29: 270---6.
• Desai, M. Y., Owens, A. T., Abraham, T., et al. (2025). Mavacamten in symptomatic nonobstructive hypertrophic cardiomyopathy. New England Journal of Medicine. PubMed.
• Ho, C. Y., Mealiffe, M. E., Bach, R. G., et al. (2020). Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy (MAVERICK-HCM). Journal of the American College of Cardiology, 75(21):        2649-2660.
• Tayon, K. G., Kusumoto, F. M., & Ali, M. (2025). A study of mavacamten in nonobstructive hypertrophic cardiomyopathy (ODYSSEY-HCM). American College of Cardiology. American College of Cardiology.
• European Society of Cardiology. (2025). No improvements with mavacamten in symptomatic nonobstructive hypertrophic cardiomyopathy. ESC Press Office.
• Fahmi OA et al. Evaluation of CYP2B6 Induction and Prediction of Clinical Drug–Drug Interactions: Considerations from the IQ Consortium Induction Working Group—An Industry Perspective. Drug Metab Dispos, 2016; 44: 1720–1730.
• Bosilkovska M et al. Geneva Cocktail for Cytochrome P450 and P-Glycoprotein Activity Assessment Using Dried Blood Spots. Clinical Pharmacology & Therapeutics, 2014; 96(3):           349–359.
• Kamiya C et al. Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype. J Pharmacol Sci., 2019; 139(4): 361-366.
• Park GJ et al. Drug-drug interaction of microdose and regular-dose omeprazole with a CYP2C19 inhibitor and inducer. Drug Des Devel Ther., 2017; 11: 1043-1053.
• Derungs A et al. Effects of Cytochrome P450 Inhibition and Induction on the Phenotyping Metrics of the Basel Cocktail: A Randomized Crossover Study. Clin Pharmacokinet, 2016; 55(1): 79-91.
• Nagai M et al. Characterization of CYP2C Induction in Cryopreserved Human Hepatocytes and Its Application in the Prediction of the Clinical Consequences of the Induction. J Pharm Sci., 2018; 107: 2479 -2488.
• Desai, M. Y., Owens, A. T., Wheeler, M. T., et al. (2024). Mavacamten for obstructive hypertrophic cardiomyopathy: Rationale for clinically guided dose titration. Journal of the American Heart Association, 13: eXXXX. (PubMed)
• [Systematic Review]. (2023). Efficacy and safety of mavacamten in HCM. Heart, Lung and irculation. (ScienceDirect)
• Cole, J., Benvie, S. F., & DeLosSantos, M. (2024). Mavacamten: A novel agent for hypertrophic cardiomyopathy. Clinical Therapeutics, 46:             368–373. (PubMed)
• Ricci, F., et al. (2024). Cardiac myosin inhibitors in hypertrophic cardiomyopathy: Clinical trials and future challenges. Biomolecules, 15(8): 1098. (MDPI)
• Jones, et al. (2025). Cardiac myosin inhibitors in hypertrophic cardiomyopathy. Journal of Cardiovascular Imaging. (SpringerLink)
• [Meta-Analysis]. (2024). Efficacy and safety of cardiac myosin inhibitors for symptomatic HCM. Frontiers in Cardiovascular Medicine, 14: 1477487. (Frontiers)
• Ho, C. Y., Mealiffe, M. E., Bach, R. G., et al. (2020). Evaluation of mavacamten in symptomatic nonobstructive HCM. Journal of the American College of Cardiology, 75(21): 2649–2660. (PubMed)
• EXPLORER-HCM and VALOR-HCM Trials. (2020–2023). NEJM / JAMA Cardiology. (PMC)If you’d like, I can format these in Vancouver or MLA style as well!
• Geske JB, Ommen SR, Gersh BJ. Hypertrophic Cardiomyopathy: Clinical Update. JACC Heart Fail., 2018 May; 6(5): 364-375.
• Sparrow AJ, Watkins H, Daniels MJ, Redwood C, Robinson P. Mavacamten rescues increased myofilament calcium sensitivity and dysregulation of Ca2+ flux causedy thin filament hypertrophic cardiomyopathy mutations. Am J Physiol Heart Circ Physiol, 2020 Mar 01; 318(3): H715-H722.
• Braunwald E, Saberi S, Abraham TP, Elliott PM, Olivotto I. Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy. Eur Heart J., 2023 Nov 21; 44(44): 4622-4633.
• Woodland M, Al-Horani RA. New Era: Mavacamten for Obstructive Hypertrophic Cardiomyopathy. Cardiovasc Hematol Agents Med Chem., 2023; 21(2): 78-83.
• Heitner SB, Jacoby D, Lester SJ, Owens A, Wang A, Zhang D, Lambing J, Lee J, Semigran M, Sehnert AJ. Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial. Ann Intern Med., 2019 Jun 04; 170(11): 741-748.
• Desai MY, Wolski K, Owens A, Naidu SS, Geske JB, Smedira NG, Schaff H, Lampl K, McErlean E, Sewell C, Zhang D, Edelberg JM, Sehnert AJ, Nissen SE. Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy. Am Heart J., 2021 Sep; 239: 80-89.
• Bishev D, Fabara S, Loseke I, Alok A, Al-Ani H, Bazikian Y. Efficacy and Safety of Mavacamten in the Treatment of Hypertrophic Cardiomyopathy: A Systematic Review. H Heart Lung Circ., 2023 Sep; 32(9): 1049-1056.